drugset / Trial / NCT05133336
Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Saroglitazar Magnesium 1 mg and 2 mg tablets for treatment of subjects with Primary Biliary Cholangitis (PBC)
Timeline
- Start
- 2022-04-01
- Primary completion
- 2025-04-30
- Completion
- 2025-05-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Saroglitazar | Small molecule | 1 mg | Oral |
| Subject | Saroglitazar | Small molecule | 2 mg | Oral |